Available online at www.sciencedirect.com
SciVerse ScienceDirect
www.elsevier.com/locate/bcdf

Psyllium improves glycemic control in patients with type-2 diabetes mellitus

Mark N. Feinglos[a], Roger D. Gibb[b], David L. Ramsey[b], Richard S. Surwit[c], Johnson W. McRorie[b,*]

[a]Division of Endocrinology, Metabolism and Nutrition, Duke University Medical Center, Durham, NC 27710, USA
[b]Quantitative Sciences, Procter & Gamble, 8700 Mason-Montgomery Road, Mason, OH 45040, USA
[c]Division of Medical Psychology, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA

ARTICLE INFO

Article history:
Received 4 October 2012
Received in revised form
4 February 2013
Accepted 6 February 2013

Keywords:
Psyllium
Viscous
Fiber
Diabetes
Glycemic

ABSTRACT

Objective: This double-blind, placebo-controlled clinical study was designed to evaluate the effects of psyllium on fasting blood glucose (FBG) and HbA_{1c} in patients being treated for type-2 diabetes mellitus (T2DM).

Research design and methods: Patients were randomly assigned to 1 of the 3 treatment groups: placebo, psyllium 3.4 g BID or psyllium 6.8 g BID (just prior to breakfast and dinner). Patients had a total of 9 clinic visits during the 20-week study period (8 weeks baseline, 12 weeks treatment). A total of 37 patients [12 females, 34 Caucasians, mean age 62 years] were enrolled (8 in the placebo group, 15 in the psyllium 3.4 g BID group and 14 in the psyllium 6.8 g BID group) and were included in the Intent-to-Treat analysis.

Results: Both doses of psyllium significantly ($p<0.05$) lowered FBG compared to placebo at treatment weeks 4, 8, and 12. Psyllium 6.8 g BID significantly lowered HbA_{1c} compared to placebo at Week 8 (-0.58 ± 0.18, $p=0.003$), and both the 3.4 g dose and the 6.8 g dose of psyllium significantly ($p<0.05$) lowered HbA_{1c} compared to placebo at Week 12 (-0.53 ± 0.20, $p=0.013$; -0.65 ± 0.20, $p=0.003$, respectively).

Conclusions: The improvement in glycemic control observed with psyllium in T2DM patients was above that already conferred by a restricted diet (all patients) and a stable dose of a sulfonylurea (81.1% of patients). These data support that psyllium is an effective co-therapy for improving glycemic control in patients being treated for T2DM. NCT01582282.

1. Introduction

According to a 2011 report from the Centers for Disease Control (CDC), diabetes affects 26 million people of all ages (8.3% of the total U.S. population), and 11 million U.S. adults 65 years and older (26.9%) (Center for Disease Control and Prevention, 2011). In the same report, pre-diabetes represented an even larger percentage of the US population: 35% of U.S. adults ages 20 years; 50% of those aged 65 years or older (Center for Disease Control and Prevention, 2011). If the percentage for adults ages 20 years and older is applied to the entire U.S. population in 2010, it yields an estimated 79 million Americans with pre-diabetes (Center for Disease Control and Prevention, 2011). A 2010 estimate from the Centers for Disease Control (CDC) predicts that up to 1/3 of U.S. adults will have T2DM by 2050 (Center for Disease Control

*Corresponding author. Tel.: +1 513 622 1423 (office), mobile: +1 513 504 7066; fax: +1 513 386 3542.
E-mail address: Mcrorie.jw@pg.com (J.W. McRorie).

2212-6198/$ - see front matter © 2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.bcdf.2013.02.003

and Prevention). Diabetes is the leading cause of kidney failure, non-traumatic lower-limb amputations, new cases of blindness among adults in the U.S., a major cause of heart disease and stroke, and the seventh leading cause of death in the U.S. T2DM accounts for approximately 90–95% of all diagnosed cases of diabetes in adults (Center for Disease Control and Prevention, 2011). The Diabetes Prevention Program (DPP), a large prevention study of people at high risk for diabetes, showed that lifestyle interventions reduced the development of T2DM by 58% during a 3-year period (Diabetes Prevention Program Research Group, 2002). Research has found that lifestyle interventions are more cost-effective than medications in preventing or delaying the onset of T2DM in individuals with pre-diabetes (Center for Disease Control and Prevention, 2011). One lifestyle intervention to reduce the risks associated with T2DM is increasing consumption of fiber in the diet, but not all dietary fibers have a significant effect on glycemic control.

Dietary fibers that form a viscous gel when hydrated have been shown to have a variety of health benefits. Psyllium and β-glucan, both viscous soluble fibers, are clinically proven to lower serum cholesterol, leading to United States Food and Drug Administration (FDA) recognition for reducing the risk of cardiovascular disease. It has been established for over 3 decades that the viscosity of a dietary fiber is also highly correlated with improvement in glycemic control. In a study published in 1978, volunteers underwent 50-g glucose tolerance tests with and without the addition of several dietary fibers, including guar gum, a highly viscous (gel-forming) fiber (Jenkins et al., 1978). High viscosity native guar gum was effective for flattening the glucose response, but this effect was abolished when the guar gum was hydrolyzed (reduced viscosity). The study further showed that a reduction in mean peak rise in blood glucose was highly correlated with viscosity ($r=0.926$; $P<0.01$) and a delay in mouth-to-cecum transit time ($r=0.885$; $P<0.02$). The authors concluded that delayed nutrient absorption due to increasing the viscosity of chyme was an important property of a soluble viscous fiber in normalizing glycemic control (Jenkins et al., 1978). Since that time, numerous clinical studies have shown that a single dose of psyllium, a viscous soluble fiber, can lower postprandial peak glucose in healthy subjects, and that multi-week dosing of psyllium before meals can lower both FBG and HbA_{1c} in patients with Metabolic Syndrome and T2DM (Cicero, Derosa, Bove, Imola, Borghi, & Gaddi, 2010; Fagerberg, 1982; Frati Munari, Pinto, Andraca, & Casarrubitas, 1998; Karhunenetal.,2010; Pastors, Blaisdell, Balm, Asplin, & Pohl, 1991; Rodriguez-Morán, Guerrero-Romero, & Laczano-Burciaga, 1998; Sierra et al., 2001; Ziai et al., 2005). The purpose of the current study was to assess the dose–response effects of psyllium for improving glycemic control in patients with T2DM who are already being treated with a stable dose of an oral hypoglycemic drug and/or a restricted diet.

2. Methods

We conducted a two-site, double-blind, randomized, placebo-controlled, multi-dose clinical study consisting of two phases (an 8-week lead-in phase followed by a 12-week treatment phase), with targeted enrollment of 90 patients. The study was terminated early due to slow enrollment. Patients followed a restricted diet for all 20 weeks of the study. Dietary compliance was assessed by a study dietician using 3-day food diaries completed by the patients. Patients already taking a stable dose (≥3 months) of a sulfonylurea were maintained on that dose throughout baseline and treatment periods. The study included male and female patients, age 36–80 years, with a clinical diagnosis of T2DM (at least one year prior to the study) controlled by diet and/or an oral sulfonylurea, and an HbA_{1c} level between 6% and 10%. Patients were stratified into two strata: (1) diet alone, or (2) diet and oral hypoglycemic medication. Patients in each stratum were randomly assigned to 1 of 3 treatment groups: placebo, psyllium 3.4 g BID for a total of 6.8 g/day, or psyllium 6.8 g BID for a total of 13.6 g/day. For the 12 week treatment period, patients took psyllium (Metamucil®) or the fiber-free placebo BID, just prior to breakfast and dinner. In addition to the screening visit, patients visited the clinic 9 times during the 20-week period, fasting at least 12 h prior to each visit where a blood sample was drawn for analysis. Fasting blood glucose was assessed at dosing weeks 2, 4, 8, and 12. HbA_{1c} was assessed at dosing weeks 4, 8, and 12. Analysis of covariance was used to assess mean treatment difference from placebo at dosing time points. The model included terms for treatment and baseline laboratory value. The treatment effect was relatively consistent across investigative centers, i.e. no significant treatment-by-center interaction. Investigative center had no meaningful effect on results and was not included in the final model.

The in-life portion of this study was conducted in 1988, but due to early termination, the data did not undergo a per-protocol analysis. A recent search of internal databases for clinical studies on natural fiber supplements in individuals with pre-diabetes and patients with T2DM led to the rediscovery of these dose–response data. HbA_{1c} tests in this study were conducted using a Helena (Daiichi) HA-8110 analyzer prior to harmonization of standards and reference ranges for the assay. Raw test results have been recalculated as estimated DCCT equivalent HbA_{1c} values, permitting comparison of clinical outcomes to the reference range defined by the Steffes et al. (2005) landmark study. The following transform equation was derived from summary tables presented in Kullberg, Bergström, Dinesen, Larsson, Little, Goldstein, & Arnqvist (1996) paper which defined correlations between the standard DCCT test and several other HbA_{1c} methods which were used in preceding years (DCCT Equivalent = 1.0183 × (HA-8110) + 0.8286).

3. Results

Thirty-seven patients were enrolled, 30 of whom (81.1%) were taking a stable dose of a sulfonylurea [glipizide (5 patients) or glyburide (25 patients)] for glycemic control. Four patients (2 in each psyllium treatment group) withdrew from the study (1 patient in each psyllium group due to an adverse event, 1 patient was lost to follow-up, and 1 patient had a blood glucose level outside of the protocol required levels). The